| Date | Title | | | May 10, 2012 | Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas| -Conditional Marketing Authorization Speeds Innovative New Therapy to Patients with Unmet Medical Need
SEATTLE, May 10, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) today announced that it has received conditional marketing authorization from the European Commission ("EC") for Pixuvri® (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas ("NHL"). Pixuvri ... |
|  | | Apr 20, 2012 | Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones|
-Net loss attributable to common shareholders decreases 66% over same period in 2011
- Entered into an agreement to acquire highly selective Phase 3 JAK2 inhibitor, pacritinib
- Readying Phase 3 trial for tosedostat in r/r AML/MDS following FDA feedback on clinical trial design
- Pixuvri® Marketing Authorization Application ("MAA") granted positive opinion by CHMP for conditional approval in European Union
SEATTLE, April 20, 2012 /PRNewswire via COMTEX/ --Cell Therapeutics, Inc. ("CTI" o... |
| | | Apr 19, 2012 | Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20| SEATTLE, April 19, 2012 /PRNewswire via COMTEX/ --On Friday, April 20, 2012, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA: CTIC) management team will host a conference call to discuss the Company's 2012 first quarter achievements and financial results.
Conference Call Numbers
Friday, April 20 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time 1-800-762-8779 (US Participants) 1-480-629-9645 (I... |
| | | Apr 19, 2012 | Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate for Myelofibrosis|
-Reported Lack of Blood and Platelet Side Effects Provides Attractive Regulatory and Commercial Profile over other JAK inhibitors
-Conference Call Scheduled, Today at 8:30 A.M. Eastern Time
SEATTLE and SINGAPORE, April 19, 2012 /PRNewswire via COMTEX/ --Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) and S*BIO Pte Ltd announced today that the companies have entered into an asset purchase agreement pursuant to which CTI would acquire world-wide rights to S*BIO's pacritinib, a highly s... |
| | | Apr 18, 2012 | Cell Therapeutics, Inc. (CTI) to Host Conference Call April 19, 8:30 AM ET| SEATTLE, April 18, 2012 /PRNewswire via COMTEX/ --On Thursday, April 19, 2012, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA: CTIC) management team will host a conference call.
Conference Call Numbers
Thursday, April 19 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time 1-877-941-8609 (US Participants) 1-480-629-9692 (International)
Call-back numbers for post-listening available at 11:30 a.... |
| | | Mar 27, 2012 | University of Washington's Neuro-Oncology Program to Investigate Cell Therapeutics' Drug Candidate OPAXIO™ (Paclitaxel Poliglumex) plus Radiotherapy for Glioblastoma Multiforme, a Highly Malignant Brain Cancer|
SEATTLE, March 27, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced that the University of Washington's ("UW") School of Medicine, Departments of Neurology and Neurosurgery, Division of Neuro-Oncology has begun enrolling patients in a randomized phase II clinical study comparing the combination of OPAXIO™ (paclitaxel poliglumex, PPX, CT-2103) and radiation therapy ("RT") to the combination of temozolomide ("TMZ") and RT for patients with newly-diagnosed gli... |
| | | Mar 07, 2012 | Cell Therapeutics, Inc. (CTI) Reports Fourth Quarter and Year-End Financial Results and Milestones| - Total net operating expenses and net loss down for both the fourth quarter and fiscal year 2011 compared to same periods in 2010
- Retired all outstanding convertible debt
-Pixuvri™ Marketing Authorization Application ("MAA") granted positive opinion by CHMP for conditional approval in European Union
SEATTLE, March 7, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported financial results and recent accomplishments for the fourth... |
| | | Mar 06, 2012 | Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2011 Financial Results on March 7|
SEATTLE, March 6, 2012 /PRNewswire/ -- On Wednesday, March 7, 2012, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA: CTIC) management team will host a conference call to discuss the Company's 2011 fourth quarter and year-end achievements and financial results.
Conference Call Numbers
Wednesday, March 7
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
1-877-941-8609 (US Participa... |
| | | Feb 17, 2012 | European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri™| Potentially the First Drug to be Approved as Monotherapy for the Treatment of Adult Patients with Multiple Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas (NHL)
SEATTLE, Feb. 17, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that Pixuvri™ (pixantrone dimaleate) has been granted a positive opinion for conditional approval from the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHM... |
| | | Jan 30, 2012 | Cell Therapeutics Withdraws New Drug Application for Pixuvri™ and Plans to Resubmit in 2012|
SEATTLE, Jan. 30, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has voluntarily withdrawn its New Drug Application ("NDA") for Pixuvri (pixantrone) for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") in patients who failed two or more lines of prior therapy. The NDA was withdrawn because, after communications with the U.S. Food and Drug Administration ("FDA"), CTI needed additional time to prepare for the... |
| | | Jan 20, 2012 | Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February|
SEATTLE, Jan. 20, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that, following discussions with the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP"), the CHMP may issue an opinion on CTI's Marketing Authorization Application ("MAA") for Pixuvri in mid-February. In the interim, CTI will continue to work with the CHMP on the Summary of Product Characteristics and other labeling items for Pix... |
| | | Jan 03, 2012 | FDA's Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012|
SEATTLE, Jan. 3, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that on February 9, 2012 the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review CTI's resubmitted New Drug Application (NDA) for pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) in patients who failed two or more lines of prior therapy. ODAC is a panel of experts that evaluates da... |
| |
|
